Aspire Biopharma Holdings (ASBP) EBITDA Margin (2025 - 2026)
Aspire Biopharma Holdings (ASBP) posted quarterly EBITDA Margin of 5805.98% for Q1 2026, up 86.62% quarter-over-quarter from 43403.52% in Q4 2025.
Aspire Biopharma Holdings (ASBP) EBITDA Margin (2025 - 2026) Analysis & Trends
Aspire Biopharma Holdings (ASBP) has reported EBITDA Margin for 2 consecutive years, with 5805.98% the latest figure, recorded in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.57 Bn | 131.72 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 86.71 Bn | 78.72 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 65.44 Bn | 60.25 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 60.06 Bn | 54.93 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 31.89 Bn | 28.58 Bn | 992.69 Mn | 17.93% |
| 7 | BioNTech SE | 28.11 Bn | 9.72 Bn | 668.28 Mn | -35.57% |
| 8 | Insmed | 27.59 Bn | 26.43 Bn | 358.27 Mn | -0.36% |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 19.75% |
| 10 | Aspire Biopharma Holdings | 8.34 Mn | -3.83 Mn | -30,086.00 | -4,244.14% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4,244.14% |
| Mar 31, 2026 | -5,805.98% |
| Dec 31, 2025 | -43,403.52% |
| Sep 30, 2025 | -59,015.82% |